292 related articles for article (PubMed ID: 34237326)
1. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.
Emma F; Hoff WV; Hohenfellner K; Topaloglu R; Greco M; Ariceta G; Bettini C; Bockenhauer D; Veys K; Pape L; Hulton S; Collin S; Ozaltin F; Servais A; Deschênes G; Novo R; Bertholet-Thomas A; Oh J; Cornelissen E; Janssen M; Haffner D; Ravà L; Antignac C; Devuyst O; Niaudet P; Levtchenko E
Kidney Int; 2021 Nov; 100(5):1112-1123. PubMed ID: 34237326
[TBL] [Abstract][Full Text] [Related]
2. CTNS mRNA molecular analysis revealed a novel mutation in a child with infantile nephropathic cystinosis: a case report.
Papizh S; Serzhanova V; Filatova A; Skoblov M; Tabakov V; van den Heuvel L; Levtchenko E; Prikhodina L
BMC Nephrol; 2019 Oct; 20(1):400. PubMed ID: 31672123
[TBL] [Abstract][Full Text] [Related]
3. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term cysteamine treatment in patients with cystinosis.
Ariceta G; Giordano V; Santos F
Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
[TBL] [Abstract][Full Text] [Related]
5. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
Nesterova G; Williams C; Bernardini I; Gahl WA
Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
[TBL] [Abstract][Full Text] [Related]
6. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
[TBL] [Abstract][Full Text] [Related]
7. Cystinosin-deficient rats recapitulate the phenotype of nephropathic cystinosis.
Hollywood JA; Kallingappa PK; Cheung PY; Martis RM; Sreebhavan S; 'Atiola RD; Chatterjee A; Buckels EJ; Matthews BG; Lewis PM; Davidson AJ
Am J Physiol Renal Physiol; 2022 Aug; 323(2):F156-F170. PubMed ID: 35695380
[TBL] [Abstract][Full Text] [Related]
8. Extrarenal complications of cystinosis.
Topaloglu R
Pediatr Nephrol; 2024 Aug; 39(8):2283-2292. PubMed ID: 38127152
[TBL] [Abstract][Full Text] [Related]
9. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
10. Nephropathic cystinosis: an update on genetic conditioning.
Topaloglu R
Pediatr Nephrol; 2021 Jun; 36(6):1347-1352. PubMed ID: 32564281
[TBL] [Abstract][Full Text] [Related]
11. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.
Veys K; Zadora W; Hohenfellner K; Bockenhauer D; Janssen MCH; Niaudet P; Servais A; Topaloglu R; Besouw M; Novo R; Haffner D; Kanzelmeyer N; Pape L; Wühl E; Harms E; Awan A; Sikora P; Ariceta G; van den Heuvel B; Levtchenko E
J Inherit Metab Dis; 2023 Jan; 46(1):43-54. PubMed ID: 36117148
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic challenge in a patient with nephropathic juvenile cystinosis: a case report.
Higashi S; Matsunoshita N; Otani M; Tokuhiro E; Nozu K; Ito S
BMC Nephrol; 2017 Sep; 18(1):300. PubMed ID: 28950840
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment of nephropathic cystinosis with cysteamine.
Kleta R; Gahl WA
Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
[TBL] [Abstract][Full Text] [Related]
16. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
[TBL] [Abstract][Full Text] [Related]
17. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
[TBL] [Abstract][Full Text] [Related]
18. Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
Hollywood JA; Przepiorski A; D'Souza RF; Sreebhavan S; Wolvetang EJ; Harrison PT; Davidson AJ; Holm TM
J Am Soc Nephrol; 2020 May; 31(5):962-982. PubMed ID: 32198276
[TBL] [Abstract][Full Text] [Related]
19. Cystinosis: clinical presentation, pathogenesis and treatment.
Ivanova E; De Leo MG; De Matteis MA; Levtchenko E
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():176-84. PubMed ID: 25345100
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
